Bufalin

Bufalin

SCHEMBL165666

C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](c3ccc(=O)oc3)CC[C@]12O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP1A1 P05023 6/20 1.00
ATP1B1 P05026 6/20 1.00
ATP1A3 P13637 6/20 1.00
ATP1B2 P14415 6/20 1.00
ATP1A2 P50993 6/20 1.00
ATP1B3 P54709 6/20 1.00
FXYD2 P54710 6/20 1.00
ATP1A4 Q13733 6/20 1.00
CYP3A4 P08684 3/20 1.00
CYP3A5 P20815 2/20 1.00
AR P10275 1/20 1.00
ZFP91 Q96JP5 1/20 1.00
CYP3A7 P24462 1/20 0.73
STAT3 P40763 1/20 0.68
RAB9A P51151 4/20 0.63
NPC1 O15118 3/20 0.63
PAX8 Q06710 2/20 0.63
ATP12A P54707 2/20 0.63
TP53 P04637 2/20 0.63
LMNA P02545 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bufalin SCHEMBL12756993 1.00 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufalin SCHEMBL16628184 1.00 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufalin SCHEMBL19415190 1.00 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufalin SCHEMBL14477877 1.00 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufalin SCHEMBL20127236 1.00 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufalin SCHEMBL23382204 1.00 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufalin SCHEMBL15864888 1.00 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufalin SCHEMBL21083171 1.00 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufalin SCHEMBL21129737 1.00 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufalin SCHEMBL8257006 1.00 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1997 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121270638-B Method for extracting bufadienolide from bufadienolide medicinal material and application 亳州学院 2026-05-15 CN claimed
CN-122005693-A Application of Jiaweidanzhi Xiaoyao powder or extract thereof in preparation of medicines for treating depression complicated with ulcerative colitis 河南中医药大学 2026-05-12 CN claimed
WO-2026086871-A1 ANTI-AGEING COMPOUNDS, USES THEREFOR, METHOD FOR IDENTIFYING, AND COMPOSITIONS CONTAINING Centre for Translational Stem Cell Biology Limited (CN) 2026-04-30 WO claimed
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY ZOUNEK ALEX (DE) 2025-12-18 US claimed
US-20250222024-A1 METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME REVERSPAH LLC (US) 2025-07-10 US claimed
US-20250205258-A1 DERIVATIVES OF BUFALIN AND THEIR PREPARATION METHODS, AS WELL AS COMPOSITIONS, PREPARATIONS, AND APPLICATIONS SHANGHAI MEWSGEN BIOTECHNOLOGY CO LTD (CN) 2025-06-26 US claimed
CN-120019812-A Artificial toad venom composition and application thereof 南京中医药大学 2025-05-20 CN claimed
EP-4551565-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY Zounek, Alex (DE) 2025-05-14 EP claimed
CN-119909196-A Composition for inhibiting tumor, nano-drug, preparation method and application 湖南新汇制药股份有限公司 2025-05-02 CN claimed
WO-2025086855-A1 AZIDE PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 中科帅天医药(深圳)有限公司 2025-05-01 WO claimed
WO-2002014343-A1 BUFADIENOLIDE DERIVATIVES AND USE AS IMMUNOSUPPRESSIVE, ANTIINFLAMMATORY AND ANALGESIC AGENTS TERNESS, PETER (DE) 2002-02-21 WO claimed
EP-1150687-A2 METHODS FOR ANTI-TUMOR THERAPY Cellpath, Inc. (US) 2001-11-07 EP claimed
WO-2000047215-A2 METHODS FOR ANTI-TUMOR THERAPY CELLPATH, INC. (US) 2000-08-17 WO claimed
EP-0988373-A1 SELECTION MARKER Karolinska Innovations AB (SE) 2000-03-29 EP claimed
US-6037326-A APPLYING TO THE SKIN AN INHIBITOR OF A DNA TOPOISOMERASE GILLETTE COMPANY, THE 2000-03-14 US claimed
WO-2000010552-A2 USE OF ANTI-ANGIOGENIC AGENTS FOR INHIBITING VESSEL WALL INJURY GLOBAL VASCULAR CONCEPTS, INC. (US) 2000-03-02 WO claimed
EP-0957891-A1 REDUCTION OF HAIR GROWTH HANDELMAN, Joseph H. (US) 1999-11-24 EP claimed
WO-1998055603-A1 NEW SELECTION MARKER KAROLINSKA INNOVATIONS AB (SE) 1998-12-10 WO claimed
WO-1998029086-A1 REDUCTION OF HAIR GROWTH HANDELMAN, JOSEPH, H. (US) 1998-07-09 WO claimed
CN-1072183-A Extract the method for bufalin and the purposes of bufalin and relevant derivative thereof ZHANG LISHA (CN) 1993-05-19 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY KIT, CTSL, PAICS ATP1A1 3241/4885ATP1B1 3180/4885ATP1A3 4201/4885
US-20250222024-A1 METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME NFKBIA, ALOX15, ALOX15B ATP1A1 867/4885ATP1B1 1538/4885ATP1A3 1454/4885
US-20250205258-A1 DERIVATIVES OF BUFALIN AND THEIR PREPARATION METHODS, AS WELL AS COMPOSITIONS, PREPARATIONS, AND APPLICATIONS KCNN1, KCNN2, KCNJ1 ATP1A1 67/4885ATP1B1 115/4885ATP1A3 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.